• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

14.37 +0.05 (+0.35%)
Streaming Delayed Price Updated: 12:16 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 66,615
Open 14.40
Bid (Size) 14.30 (1)
Ask (Size) 14.38 (1)
Prev. Close 14.32
Today's Range 14.27 - 14.50
52wk Range 9.030 - 17.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
July 17, 2025
Company to participate in investor conferences in July and August 
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge
May 30, 2025
Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of zanidatamab as part of its agreement with BeOne Medicines. 
Via Stocktwits

Performance

YTD
-2.8%
-2.8%
1 Month
+15.2%
+15.2%
3 Month
+18.2%
+18.2%
6 Month
+0.6%
+0.6%
1 Year
+40.1%
+40.1%

More News

Read More
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
May 30, 2025
From Zymeworks Inc.
Via GlobeNewswire
Earnings Scheduled For May 8, 2025
May 08, 2025
Via Benzinga
Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)
March 10, 2025
Via Benzinga
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
May 22, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
May 21, 2025
From Zymeworks Inc.
Via GlobeNewswire
TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy
May 21, 2025
Via Stocktwits
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
May 19, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 08, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
April 25, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
April 21, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
April 17, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
March 26, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
March 25, 2025
From Zymeworks Inc.
Via GlobeNewswire
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
March 06, 2025
Via Benzinga
Topics Earnings
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 05, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
February 26, 2025
From Zymeworks Inc.
Via GlobeNewswire
Earnings Scheduled For March 5, 2025
March 05, 2025
Via Benzinga
Zymeworks Announces Participation in Upcoming Investor Conferences
February 25, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
February 18, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
February 13, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
January 30, 2025
From Zymeworks Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 23, 2025
Via Benzinga
Zymeworks in Focus for Insider Activity: Catalysts Ahead
January 10, 2025
Via MarketBeat

Frequently Asked Questions

Is Zymeworks Inc. - Common Stock publicly traded?
Yes, Zymeworks Inc. - Common Stock is publicly traded.
What exchange does Zymeworks Inc. - Common Stock trade on?
Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zymeworks Inc. - Common Stock?
The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
What is the current price of Zymeworks Inc. - Common Stock?
The current price of Zymeworks Inc. - Common Stock is 14.37
When was Zymeworks Inc. - Common Stock last traded?
The last trade of Zymeworks Inc. - Common Stock was at 07/23/25 12:16 PM ET
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap